TY - JOUR
T1 - The association between charlson comorbidity index and the medical care cost of cancer
T2 - A retrospective study
AU - Yoon, Seok Jun
AU - Kim, Eun Jung
AU - Seo, Hyun Ju
AU - Oh, In Hwan
PY - 2015
Y1 - 2015
N2 - Background. This study compared comorbidity-related medical care cost associated with different types of cancer, by examining breast (N=287), colon (N=272), stomach (N=614), and lung (N=391) cancer patients undergoing surgery. Methods. Using medical benefits claims data, we calculated Charlson Comorbidity Index (CCI) and total medical cost. The effect of comorbidity on the medical care cost was investigated using multiple regression and logistic regression models and controlling for demographic characteristics and cancer stage. Results. The treatment costs incurred by stomach and colon cancer patients were 1.05- and 1.01-fold higher, respectively, in patients with higher CCI determined. For breast cancer, the highest costs were seen in those with chronic obstructive pulmonary disease (COPD), but the increase in cost reduced as CCI increased. Colon cancer patients with diabetes mellitus and a CCI = 1 score had the highest medical costs. The lowest medical costs were incurred by lung cancer patients with COPD and a CCI = 2 score. Conclusion. The comorbidities had a major impact on the use of medical resources, with chronic comorbidities incurring the highest medical costs. The results indicate that comorbidities affect cancer outcomes and that they must be considered strategies mitigating cancer's economic and social impact.
AB - Background. This study compared comorbidity-related medical care cost associated with different types of cancer, by examining breast (N=287), colon (N=272), stomach (N=614), and lung (N=391) cancer patients undergoing surgery. Methods. Using medical benefits claims data, we calculated Charlson Comorbidity Index (CCI) and total medical cost. The effect of comorbidity on the medical care cost was investigated using multiple regression and logistic regression models and controlling for demographic characteristics and cancer stage. Results. The treatment costs incurred by stomach and colon cancer patients were 1.05- and 1.01-fold higher, respectively, in patients with higher CCI determined. For breast cancer, the highest costs were seen in those with chronic obstructive pulmonary disease (COPD), but the increase in cost reduced as CCI increased. Colon cancer patients with diabetes mellitus and a CCI = 1 score had the highest medical costs. The lowest medical costs were incurred by lung cancer patients with COPD and a CCI = 2 score. Conclusion. The comorbidities had a major impact on the use of medical resources, with chronic comorbidities incurring the highest medical costs. The results indicate that comorbidities affect cancer outcomes and that they must be considered strategies mitigating cancer's economic and social impact.
UR - http://www.scopus.com/inward/record.url?scp=84939504285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939504285&partnerID=8YFLogxK
U2 - 10.1155/2015/259341
DO - 10.1155/2015/259341
M3 - Article
C2 - 26347086
AN - SCOPUS:84939504285
VL - 2015
JO - BioMed Research International
JF - BioMed Research International
SN - 2314-6133
M1 - 259341
ER -